Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Centre Hospitalier Universitaire de Nice |
---|---|
Information provided by: | Centre Hospitalier Universitaire de Nice |
ClinicalTrials.gov Identifier: | NCT00833274 |
Apathy, defined as a lack of motivation in behaviour, cognition and affect, is common in neurodegenerative diseases. Specific scales are available for the evaluation of apathy but it lacks objective evaluation methods. The aim of this study is to evaluate the changes in reaction time task according to the presence or absence of reward stimulation and to assess the relation between these performances and apathy scales.
Condition | Intervention |
---|---|
Alzheimer Disease |
Behavioral: computerized test |
Study Type: | Interventional |
Study Design: | Diagnostic, Open Label, Uncontrolled, Parallel Assignment |
Official Title: | Evaluation of Apathy Using Attentional Reaction Test in Neurodegenerative Diseases |
Estimated Enrollment: | 100 |
Study Start Date: | February 2009 |
Estimated Study Completion Date: | May 2010 |
Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
|
Behavioral: computerized test
Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
|
MATERIAL: 13 patients with Mild Cognitive Impairment (MCI), 15 patients with Alzheimer's disease (AD) and 91 elderly healthy subjects were enrolled. A computerized test using the experiment software E-prime® was designed to assess reaction times (in ms) in different experimental conditions after a training trial (neutral, stimulation, stress, stimulation after stress, extinction) and relation between the performances to the test and the Apathy Inventory (AI) scores (lack of initiative, lack of interest, emotional blunting) were observed. METHOD: Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white. After pressing the button, a randomized colorized geometric figure appears on the screen, and disappears automatically after a few seconds, replaced by a new white screen.
Reaction time (in ms) between a white screen and a press of the button is analysed. After a training trial, reaction times are analysed in different experimental conditions: neutral - stimulation1 (patient gets points when pressing the button) - stress (alarm) - stimulation2 (patient gets points when pressing, after the stress trial) - extinction (similar to neutral condition).
Ages Eligible for Study: | 65 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Philippe ROBERT, MD, PhD | 0492034770 |
France | |
CM2R, Nice University Hospital | Recruiting |
NICE, France, 06000 | |
Contact: Philippe ROBERT, MD,PhD robert.ph@chu-nice.fr | |
Contact: Renaud DAVID, MD david.r@chu-nice.fr | |
Principal Investigator: Philippe ROBERT, MD, PhD | |
Sub-Investigator: Renaud DAVID, MD |
Responsible Party: | CHU de Nice ( Departement de la Recherche Clinique et de l'Innovation ) |
Study ID Numbers: | 06-CIR-01 |
Study First Received: | January 28, 2009 |
Last Updated: | April 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00833274 History of Changes |
Health Authority: | France: Direction Générale de la Santé; France: French Data Protection Authority; France: Institutional Ethical Committee |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Alzheimer Disease Central Nervous System Diseases Brain Diseases |
Dementia Neurodegenerative Diseases Cognition Disorders Delirium |
Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Nervous System Diseases Alzheimer Disease Central Nervous System Diseases |
Tauopathies Brain Diseases Dementia Neurodegenerative Diseases |